INVA
INVA
NASDAQ · Pharmaceuticals

Innoviva Inc

$22.06
+0.14 (+0.64%)
As of Mar 25, 1:41 PM ET ·
Financial Highlights (FY 2026)
Revenue
364.61M
Net Income
23.78M
Gross Margin
89.8%
Profit Margin
6.5%
Rev Growth
-2.9%
D/E Ratio
0.65
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 89.8% 89.8% 67.3% 67.3%
Operating Margin 46.5% 41.9% 36.7% 43.7%
Profit Margin 6.5% 6.2% 33.9% 33.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 364.61M 375.54M 296.49M 325.02M
Gross Profit 327.42M 337.23M 199.68M 218.90M
Operating Income 169.62M 157.23M 108.77M 141.90M
Net Income 23.78M 22.04M 100.45M 107.69M
Gross Margin 89.8% 89.8% 67.3% 67.3%
Operating Margin 46.5% 41.9% 36.7% 43.7%
Profit Margin 6.5% 6.2% 33.9% 33.1%
Rev Growth -2.9% -2.9% +12.4% +2.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 347.73M 347.73M 569.66M 644.56M
Total Equity 536.04M 536.04M 1.17B 1.19B
D/E Ratio 0.65 0.65 0.49 0.54
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 192.89M 188.74M 161.71M 177.91M
Free Cash Flow 84.32M 106.96M